Ultragenyx Posts $173M in Q3 Revenue, Down From Q2's $214M
RARE sits 31% above its 52-week low of $12.73.
Summary
Ultragenyx reported third-quarter revenue of $173M, a step down from the $214M it booked in Q2 2026, along with a third-quarter loss of $118M, or $1.16 a share. The sequential decline comes as the company digests a turbulent stretch: the FDA approved its GSDIa gene therapy in August and FAYUVI for Sanfilippo syndrome type A in September, while the Phase 3 Aspire trial for apazunersen in Angelman syndrome failed in early September and sent shares down more than 40% premarket. The company also lined up $210M in cash from selling its priority review voucher in October, which supports the balance sheet while the newly approved therapies ramp. Alongside the results, the company announced substantial expense reductions and reaffirmed profitability in 2027.
At the time of this announcement, RARE was trading at $16.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.73 to $39.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.